Common Side Effects of Evkeeza
Evkeeza (evinacumab-dgnb), approved for homozygous familial hypercholesterolemia (HoFH)—a genetic high cholesterol condition—most often causes injection-site reactions like pain, redness, or bruising at the IV infusion site. These affect about 40-50% of patients in clinical trials. Other frequent issues include upper respiratory tract infections (around 25%) and joint pain (arthralgia, about 10%).[1][2]
Serious or Less Common Side Effects
Rare but serious risks include severe allergic reactions (hypersensitivity), such as rash, itching, swelling, or anaphylaxis, which can occur during or after infusion—monitor closely for the first few hours. Infusion-related reactions like chills, fever, or hypertension happen in under 5% of cases. No major liver toxicity or muscle breakdown (rhabdomyolysis) signals emerged in trials, unlike some statins.[1][3]
How Side Effects Compare to Statins for High Cholesterol
Evkeeza targets ANGPTL3 protein to lower LDL differently from statins, which block cholesterol production. Statin users often report muscle pain (5-10%) or liver enzyme rises, but Evkeeza avoids these—making it suitable for statin-intolerant HoFH patients. However, its infusion requirement (monthly IV) adds procedural discomfort absent in pills.[2][4]
Who Experiences Side Effects and Risk Factors
Side effects hit most in the first year of treatment, tapering later. Children (5+ years) in trials saw similar profiles to adults, but data is limited for under-5s or non-HoFH use (off-label for other high cholesterol). Pre-existing allergies or infusion history raise reaction risks; pregnant patients should avoid it due to unknown fetal effects.[1][3]
Managing and Reporting Side Effects
Premedicate with antihistamines or acetaminophen if prior reactions occur. Stop infusions for severe hypersensitivity. Patients report issues via FDA MedWatch or doctors. Long-term data (beyond 2 years) remains emerging from post-approval studies.[2][5]
[1]: Evkeeza Prescribing Information (FDA)
[2]: ClinicalTrials.gov - ELIPSE HoFH Trial (NCT03397121)
[3]: Regeneron Evkeeza Safety Profile
[4]: NEJM - Evinacumab for HoFH (2021)
[5]: FDA Adverse Event Reporting System (FAERS) Summary for Evkeeza